Initiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity

Carolina Malta Hansen; Jonas Bjerring Olesen; Morten Lock Hansen; Aziza Azimi; Christian Torp-Pedersen; Helena Dominguez

doi:10.3389/fphar.2012.00123

Initiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity

Carolina Malta Hansen, Jonas Bjerring Olesen, Morten Lock Hansen, Aziza Azimi, Christian Torp-Pedersen, Helena Dominguez

3 Citationer (Scopus)

Abstract

The aim of this study was to investigate initiation of and persistence with warfarin treatment in patients with atrial fibrillation (AF) according to ethnicity. Patients hospitalized with first-time AF from 1997 to 2009, prescription claims of warfarin and country of birth were identified by individual-level linkage of nationwide administrative agencies. Cox proportional hazards models were used to estimate the relationship between covariates affecting initiation and non-persistence with warfarin treatment. A total of 151,537 patientswere included in the study and 5,061(3.3%) were of non-Danish origin. CHADS2 score distribution varied substantially according to ethnicity, the proportion of patients with CHADS2 score ≥1 being 79.2, 78.1, 65.9, and 46.0% for patients of Danish,Western, Eastern, and African origin, respectively. 79,239(52.4%) of all patients initiated treatment with warfarin at some point in time. Multivariable Cox proportional hazard analyses indicated patients of Eastern and African origin were less likely to initiate warfarin therapy (HR 0.75; 95% CI 0.69-0.82 and HR 0.58; 95% CI 0.44-0.76, respectively). Patients of Eastern origin were more likely to interrupt treatmets with CHADS2 score >1). African origin was associated with a trend to interrupnt (HR 1.23; 95% CI 1.02-1.47; for all patients; HR 1.62; 95% CI 1.22-2.16; for patient treatment (HR 1.44; 95% CI 0.46-4.47; for patients with CHADS2 score >1). Initiation of and persistence withwarfarin in AF patients is lower among patients of Eastern and African origin compared to patients of Danish andWestern origin, despite equal access to health care and medication. Future studies should address, beyond ethnicity, all possible driving factors of (non)initiation and persistence with treatment in general.This will be particularly interesting in light of the new generation of anticoagulants, which might render different adherence to treatment.

Originalsprog	Engelsk
Tidsskrift	Frontiers in Pharmacology
Vol/bind	3
Sider (fra-til)	123
ISSN	1663-9812
DOI	https://doi.org/10.3389/fphar.2012.00123
Status	Udgivet - 2012

Adgang til dokumentet

10.3389/fphar.2012.00123

Citationsformater

@article{d1b62a34faae48eaad6f69d5a6b7ac34,

title = "Initiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity",

abstract = "The aim of this study was to investigate initiation of and persistence with warfarin treatment in patients with atrial fibrillation (AF) according to ethnicity. Patients hospitalized with first-time AF from 1997 to 2009, prescription claims of warfarin and country of birth were identified by individual-level linkage of nationwide administrative agencies. Cox proportional hazards models were used to estimate the relationship between covariates affecting initiation and non-persistence with warfarin treatment. A total of 151,537 patientswere included in the study and 5,061(3.3%) were of non-Danish origin. CHADS2 score distribution varied substantially according to ethnicity, the proportion of patients with CHADS2 score ≥1 being 79.2, 78.1, 65.9, and 46.0% for patients of Danish,Western, Eastern, and African origin, respectively. 79,239(52.4%) of all patients initiated treatment with warfarin at some point in time. Multivariable Cox proportional hazard analyses indicated patients of Eastern and African origin were less likely to initiate warfarin therapy (HR 0.75; 95% CI 0.69-0.82 and HR 0.58; 95% CI 0.44-0.76, respectively). Patients of Eastern origin were more likely to interrupt treatmets with CHADS2 score >1). African origin was associated with a trend to interrupnt (HR 1.23; 95% CI 1.02-1.47; for all patients; HR 1.62; 95% CI 1.22-2.16; for patient treatment (HR 1.44; 95% CI 0.46-4.47; for patients with CHADS2 score >1). Initiation of and persistence withwarfarin in AF patients is lower among patients of Eastern and African origin compared to patients of Danish andWestern origin, despite equal access to health care and medication. Future studies should address, beyond ethnicity, all possible driving factors of (non)initiation and persistence with treatment in general.This will be particularly interesting in light of the new generation of anticoagulants, which might render different adherence to treatment.",

author = "Hansen, {Carolina Malta} and Olesen, {Jonas Bjerring} and Hansen, {Morten Lock} and Aziza Azimi and Christian Torp-Pedersen and Helena Dominguez",

year = "2012",

doi = "10.3389/fphar.2012.00123",

language = "English",

volume = "3",

pages = "123",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Initiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity

AU - Hansen, Carolina Malta

AU - Olesen, Jonas Bjerring

AU - Hansen, Morten Lock

AU - Azimi, Aziza

AU - Torp-Pedersen, Christian

AU - Dominguez, Helena

PY - 2012

Y1 - 2012

N2 - The aim of this study was to investigate initiation of and persistence with warfarin treatment in patients with atrial fibrillation (AF) according to ethnicity. Patients hospitalized with first-time AF from 1997 to 2009, prescription claims of warfarin and country of birth were identified by individual-level linkage of nationwide administrative agencies. Cox proportional hazards models were used to estimate the relationship between covariates affecting initiation and non-persistence with warfarin treatment. A total of 151,537 patientswere included in the study and 5,061(3.3%) were of non-Danish origin. CHADS2 score distribution varied substantially according to ethnicity, the proportion of patients with CHADS2 score ≥1 being 79.2, 78.1, 65.9, and 46.0% for patients of Danish,Western, Eastern, and African origin, respectively. 79,239(52.4%) of all patients initiated treatment with warfarin at some point in time. Multivariable Cox proportional hazard analyses indicated patients of Eastern and African origin were less likely to initiate warfarin therapy (HR 0.75; 95% CI 0.69-0.82 and HR 0.58; 95% CI 0.44-0.76, respectively). Patients of Eastern origin were more likely to interrupt treatmets with CHADS2 score >1). African origin was associated with a trend to interrupnt (HR 1.23; 95% CI 1.02-1.47; for all patients; HR 1.62; 95% CI 1.22-2.16; for patient treatment (HR 1.44; 95% CI 0.46-4.47; for patients with CHADS2 score >1). Initiation of and persistence withwarfarin in AF patients is lower among patients of Eastern and African origin compared to patients of Danish andWestern origin, despite equal access to health care and medication. Future studies should address, beyond ethnicity, all possible driving factors of (non)initiation and persistence with treatment in general.This will be particularly interesting in light of the new generation of anticoagulants, which might render different adherence to treatment.

AB - The aim of this study was to investigate initiation of and persistence with warfarin treatment in patients with atrial fibrillation (AF) according to ethnicity. Patients hospitalized with first-time AF from 1997 to 2009, prescription claims of warfarin and country of birth were identified by individual-level linkage of nationwide administrative agencies. Cox proportional hazards models were used to estimate the relationship between covariates affecting initiation and non-persistence with warfarin treatment. A total of 151,537 patientswere included in the study and 5,061(3.3%) were of non-Danish origin. CHADS2 score distribution varied substantially according to ethnicity, the proportion of patients with CHADS2 score ≥1 being 79.2, 78.1, 65.9, and 46.0% for patients of Danish,Western, Eastern, and African origin, respectively. 79,239(52.4%) of all patients initiated treatment with warfarin at some point in time. Multivariable Cox proportional hazard analyses indicated patients of Eastern and African origin were less likely to initiate warfarin therapy (HR 0.75; 95% CI 0.69-0.82 and HR 0.58; 95% CI 0.44-0.76, respectively). Patients of Eastern origin were more likely to interrupt treatmets with CHADS2 score >1). African origin was associated with a trend to interrupnt (HR 1.23; 95% CI 1.02-1.47; for all patients; HR 1.62; 95% CI 1.22-2.16; for patient treatment (HR 1.44; 95% CI 0.46-4.47; for patients with CHADS2 score >1). Initiation of and persistence withwarfarin in AF patients is lower among patients of Eastern and African origin compared to patients of Danish andWestern origin, despite equal access to health care and medication. Future studies should address, beyond ethnicity, all possible driving factors of (non)initiation and persistence with treatment in general.This will be particularly interesting in light of the new generation of anticoagulants, which might render different adherence to treatment.

U2 - 10.3389/fphar.2012.00123

DO - 10.3389/fphar.2012.00123

M3 - Journal article

C2 - 22754529

SN - 1663-9812

VL - 3

SP - 123

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

ER -

Initiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater